



## Cue Health to Announce Third Quarter 2023 Financial Results

October 25, 2023 8:01 PM EDT

SAN DIEGO--(BUSINESS WIRE)--Oct. 25, 2023-- Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its third quarter 2023 financial results on Wednesday, November 8, 2023. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

To access the live call via telephone, please register in advance using the link [here](#). Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call.

The live webinar of the call may be accessed by visiting the Events section of the Company's website at [investors.cuehealth.com](https://investors.cuehealth.com). A replay of the webinar will be available on the Company's website shortly after the conclusion of the call.

### About Cue Health

Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. The Cue Health platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's customers include federal and state public sector agencies and the private sector, which includes healthcare providers, enterprises, and individual consumers. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive this FDA approval. Cue also received Emergency Use Authorization from the FDA for its molecular mpox test at the point-of-care. To further expand its test menu, Cue has made other submissions that are now under review by the FDA, including for the Cue® Flu A/B + COVID-19 Molecular Test and the Cue® RSV Molecular Test, both of which are designed for at-home and point-of-care use. Cue, founded in 2010, owns over 100 patents and is headquartered in San Diego. For more information, please visit [www.cuehealth.com](https://www.cuehealth.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231025996867/en/): <https://www.businesswire.com/news/home/20231025996867/en/>

Lorna Williams  
[lr@cuehealth.com](mailto:lr@cuehealth.com)  
858-667-4934 (ext. 1104)

Cue Health  
[press@cuehealth.com](mailto:press@cuehealth.com)

Source: Cue Health Inc.